Evaulation of therapeutic benefits of HBV nucleocapsid assembly inhibitors

描述(由申请人提供)：这是一项确定新发现的苯甲酰胺衍生物(BAS)作为单一治疗药物或与核苷类似物联合治疗慢性乙肝的可行性和疗效的提案。在我们实验室中，BAS被确认为乙肝病毒(乙肝病毒)前基因组(PG)RNA包裹的抑制剂，这是后续病毒DNA合成所必需的。它们在机制上与目前FDA批准的抗病毒药物截然不同，因此应该是它们的补充。此外，抑制pgRNA包膜或核衣壳组装，不仅会阻止病毒基因组的复制和病毒粒子的产生，还可能扰乱HBVpgRNA-逆转录酶(RT)复合体和核心蛋白的代谢，从而干扰宿主在感染肝细胞中的先天抗病毒免疫反应和cccDNA功能。与迄今报道的其他pgRNA包膜抑制剂不同，我们的苯甲酰胺pgRNA包膜抑制剂还有效地抑制土拨鼠肝炎病毒(WHV)，这允许评估这类抗病毒药物在 首次建立了庚型肝炎病毒慢性感染动物模型。因此，我们建议在该项目中进行进一步的先导优化，并开发具有最有利的ADME、安全性和药代动力学(PK)特征的化合物，用于体内感染WHV的土拨鼠的抗病毒疗效研究。同时，我们将继续努力了解BAs抑制乙肝病毒核衣壳组装的分子机制，以及它们对乙肝病毒与宿主肝细胞相互作用的影响。随着这个项目的完成，我们将更好地了解pgRNA包裹靶向抗病毒治疗的潜在临床益处，无论是单独治疗还是与核苷类似物联合治疗， 以及对开发治疗慢性肝炎的抗病毒药物的战略见解 B类感染的总体情况。将相应地作出关于铅BAS化合物的进一步临床前/临床开发的决定。

DESCRIPTION (provided by applicant): This is a proposal to determine the feasibility and therapeutic benefits of newly discovered benzamide derivatives (BAs) as mono-therapeutic agents or in combination with nucleoside analogues for the treatment of chronic hepatitis B. BAs were identified in our laboratory as inhibitors of hepatitis B virus (HBV) pregenomic (pg) RNA encapsidation, which is essential for the subsequent viral DNA synthesis. They are mechanistically distinct from, and should thus complement, the currently FDA-approved antiviral medications. In addition, inhibition of pgRNA encapsidation, or the nucleocapsid assembly, should not only preclude HBV genome replication and virion production, it might also disrupt the metabolism of HBV pgRNA-reverse transcriptase (RT) complex and core protein, which could consequentially interfere with the host innate antiviral immune response and cccDNA function in the infected hepatocytes. Unlike other pgRNA encapsidation inhibitors reported thus far, our benzamide pgRNA encapsidation inhibitors also effectively inhibit woodchuck hepatitis virus (WHV), which allows for the evaluation of the therapeutic benefits of this class of antivirals in a hepadnavirus chronically infected animal model for the first time. We, therefore, propose in this project to perform further lead optimization, and advance compounds with the most favorable ADME, safety and pharmacokinetic (PK) profiles for antiviral efficacy study in the WHV-infected woodchucks in vivo. Meanwhile, we will continue our efforts toward understanding the molecular mechanism by which BAs inhibit HBV nucleocapsid assembly and their consequential impacts on the interaction between HBV and its host hepatocytes. At the completion of this project, we will have a better understanding of the potential clinical benefits of pgRNA encapsidation-targeted antiviral therapy, either alone or in combination with nucleoside analogues in particular, and strategic insights in to the development of antiviral regimes for the cure of chronic hepatitis B infection in general. A decision on further preclinical/clinical development of the lead BAs compounds will be made accordingly.